Design, synthesis, and cytotoxic evaluation of novel scopoletin derivatives.

about

Design, synthesis, and cytotoxic evaluation of novel scopoletin derivatives.

Item

http://www.wikidata.org/entity/Q48155824

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Design, synthesis, and cytotoxic evaluation of novel scopoletin derivatives.

@en

Design, synthesis, and cytotoxic evaluation of novel scopoletin derivatives.

@nl

type

Item

label

Design, synthesis, and cytotoxic evaluation of novel scopoletin derivatives.

@en

Design, synthesis, and cytotoxic evaluation of novel scopoletin derivatives.

@nl

prefLabel

Design, synthesis, and cytotoxic evaluation of novel scopoletin derivatives.

@en

Design, synthesis, and cytotoxic evaluation of novel scopoletin derivatives.

@nl

P1476

Design, synthesis, and cytotoxic evaluation of novel scopoletin derivatives.

@en

P2093

Fuqin Guan

http://www.w3.org/2001/XMLSchema#string

Jinlu Zhang

http://www.w3.org/2001/XMLSchema#string

Na Bao

http://www.w3.org/2001/XMLSchema#string

Wei Shi

http://www.w3.org/2001/XMLSchema#string

P2860

Developing irreversible inhibitors of the protein kinase cysteinome

Electrophilic Fragment-Based Design of Reversible Covalent Kinase Inhibitors

Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions

Design of reversible, cysteine-targeted Michael acceptors guided by kinetic and computational analysis.

Scopoletin induces apoptosis in human promyeloleukemic cells, accompanied by activations of nuclear factor kappaB and caspase-3.

SC-III3, a novel scopoletin derivative, induces cytotoxicity in hepatocellular cancer cells through oxidative DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation

Irreversible protein kinase inhibitors: balancing the benefits and risks.

Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.

Coumarin hybrids as novel therapeutic agents.

Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies.

P304

641-646

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CBDD.13120

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jianbo Sun

Li Chen

P577

2017-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29052945

http://www.w3.org/2001/XMLSchema#string

P921

cytotoxicity